title: Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study.
abstract: OBJECTIVE
  To evaluate efficacy and safety of oral beclometasone dipropionate (BDP) when added to 5-ASA in the treatment of patients with active ulcerative colitis.
  
  
  METHODS
  In a 4-week, placebo-controlled, double-blind study, patients with extensive or left-sided mild to moderate active ulcerative colitis were randomized to receive oral 5-ASA (3.2 g/day) plus BDP (5 mg/day) or placebo. Clinical, endoscopic and histologic features, and haematochemical parameters were recorded at baseline and at the end of the study.
  
  
  RESULTS
  One hundred and nineteen patients were enrolled and randomly treated with BDP plus 5-ASA (n = 58) or placebo plus 5-ASA (n = 61). Both treatment groups showed a statistically significant decrease of disease activity index (DAI) and histology score at the end of treatment (P = 0.001, each). DAI score was lower in the BDP group than in the placebo group (P = 0.014), with more patients in clinical remission in the BDP group (58.6% vs. 34.4%, P = 0.008). Serum cortisol levels significantly decreased in BDP group vs. baseline (P = 0.002), but without signs of pituitary-adrenal function depletion. A low incidence of adverse events was observed in both groups.
  
  
  CONCLUSIONS
  Oral BDP in combination with oral 5-ASA is significantly more effective than 5-ASA alone in the treatment of patients with extensive or left-sided active ulcerative colitis.
authors.affiliation: Institute of Clinical Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Rizzello
authors.forename: P
authors.initials: P
authors.lastname: Gionchetti
authors.forename: A
authors.initials: A
authors.lastname: D'Arienzo
authors.forename: F
authors.initials: F
authors.lastname: Manguso
authors.forename: G
authors.initials: G
authors.lastname: Di Matteo
authors.forename: V
authors.initials: V
authors.lastname: Annese
authors.forename: D
authors.initials: D
authors.lastname: Valpiani
authors.forename: T
authors.initials: T
authors.lastname: Casetti
authors.forename: S
authors.initials: S
authors.lastname: Adamo
authors.forename: A
authors.initials: A
authors.lastname: Prada
authors.forename: G N
authors.initials: GN
authors.lastname: Castiglione
authors.forename: G
authors.initials: G
authors.lastname: Varoli
authors.forename: M
authors.initials: M
authors.lastname: Campieri
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001507:Beclomethasone / Q000008:administration & dosage / Q000494:pharmacology*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D010919:Placebos; D001507:Beclomethasone; D006854:Hydrocortisone